US EditionTwo-week radiotherapy proven as safe and effective as eight-week course for prostate cancer: 10-year follow-up
- Swedish researchers shared 10-year findings from the HYPO-RT-PC trial at ESTRO 2025, demonstrating that a condensed two-and-a-half-week radiotherapy regimen matches the safety and efficacy of the conventional eight-week treatment for localized prostate cancer.
- This large Phase III study included a cohort of 1,200 patients diagnosed with localized prostate cancer at intermediate to high risk, aiming to evaluate shorter radiotherapy regimens amid concerns about traditional treatment duration and healthcare resource demands.
- Failure-Free survival was 72% in the short-course group and 65% in the standard group, with similar urinary and bowel side effects reported in both groups after a decade.
- Associate Professor Per Nilsson highlighted that the extended follow-up results support earlier five-year data, demonstrating that administering fewer higher doses within a shorter timeframe achieves similarly effective and safe cancer control.
- The findings suggest shorter radiotherapy schedules could reduce patient disruption and healthcare costs without compromising effectiveness, potentially changing prostate cancer treatment practices.
12 Articles
12 Articles
Two-week radiotherapy proven as safe and effective as eight-week course for prostate cancer: 10-year follow-up
Prostate cancer is the most commonly diagnosed cancer in men worldwide, accounting for more than 1.4 million new cases each year. For many patients, radiotherapy is a standard treatment option that offers outcomes comparable to surgery, particularly for localized disease.
"In prostate cancer, the most important thing is awareness and early detection."
By CNN Radio Argentina Carlos Silva, Medical Director of the Argentine League for the Fight Against Cancer, MN 62,549, spoke about the importance of early detection of prostate cancer. On CNN Primera Maña, he stated that “more than 12,000 cases are diagnosed each year in Argentina and it accounts for 20.4% of all diagnosed cancers. It is the third most common but not the most deadly, which is lung cancer.” Regarding risk factors, he explained th…
Gold-standard prostate surgery now available at the Trust | Sandwell and West Birmingham NHS Trust
An innovative treatment for enlarged prostates is now being offered to NHS patients in Sandwell and West Birmingham for the first time with improved recovery times and long-term benefits. Holmium Laser Enucleation of the Prostate, or HoLEP, is a minimally invasive procedure performed under general anaesthetic and involves using a laser to remove parts of the prostate. It is now being performed by urologists at Sandwell and West Birmingham NHS Tr…
Smarter prostate cancer detection via urine
Scientists have discovered specific markers in urine that can signal the presence of prostate cancer. This breakthrough may lead to a simpler and more accurate method for detecting this life threatening disease. Prostate cancer remains one of the leading causes of death among men worldwide. Each year thousands of lives are lost to this illness and millions of new cases are diagnosed. One of the key challenges in diagnosing prostate cancer early …
Liberia and U.S. Health Partners to launch prostate Cancer Research Program - Liberia news The New Dawn Liberia, premier resource for latest news
A new initiative to institutionalize research on prostate cancer in Liberia is expected to kick off here with both Liberian and American institutions. By Kruah Thompson Monrovia, Liberia: May 1, 2025 – A group of Liberian and American medical institutions has come together to conduct biomedical research on prostate cancer in Liberia. The John F. Kennedy Memorial Hospital, the Monrovia School of Medicine, and the A.M. Dogliotti College of Medicin…
Coverage Details
Bias Distribution
- 80% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
